The effects of eslicarbazepine on persistent Na+ current and the role of the Na+ channel β subunits

Epilepsy Research

Volumn 108, Issue 2, 2014, Pages 202-211

  Doeser, Anna ^a   Soares da Silva, Patricio ^b,c   Beck, Heinz ^a   Uebachs, Mischa ^a  

^a UNIVERSITY OF BONN   (Germany)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^c University of Porto   (Portugal)

Author keywords

Carbamazepine; Epilepsy; Eslicarbazepine; INaP; Persistent sodium current; Sodium channel beta subunits

Indexed keywords

CARBAMAZEPINE; EPILEPSY; ESLICARBAZEPINE; I(NAP); PERSISTENT SODIUM CURRENT; SODIUM CHANNEL BETA SUBUNITS;

ACTION POTENTIALS; ANIMALS; ANTICONVULSANTS; DIBENZAZEPINES; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; SODIUM CHANNELS; VOLTAGE-GATED SODIUM CHANNEL BETA-1 SUBUNIT;

EID: 84895076823     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.11.022     Document Type: Article

References (50)

1. Almeida L., Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurother. J. Am. Soc. Exp. Neurother. 2007, 4:88-96.
2. Ben-Menachem E., Gabbai A.A., Hufnagel A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010, 89:278-285.
3. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 2010, 9:68-82.
4. Bialer M., Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012, 53:935-946.
5. Bonifácio M.J., Sheridan R.D., Parada A., Cunha R.A., Patmore L., Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001, 42:600-608.
6. + channels: potential for beta subunits as therapeutic targets. Expert Opin. Ther. Targets 2008, 12:1191-1203.
7. Brackenbury W.J., Isom L.L. Na channel β subunits: overachievers of the ion channel family. Front. Pharmacol. 2011, 2:53.
8. Catterall W.A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000, 26:13-25.
9. Catterall W.A., Goldin A.L., Waxman S.G. International Union of Pharmacology XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57:397-409.
10. Catterall W.A., Dib-Hajj S., Meisler M.H., Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J. Neurosci. Off. J. Soc. Neurosci. 2008, 28:11768-11777.
11. Chen C., Bharucha V., Chen Y., Westenbroek R.E., Brown A., Malhotra J.D., et al. Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:17072-17077.
12. Chen C., Westenbroek R.E., Xu X., Edwards C.A., Sorenson D.R., Chen Y., et al. Mice lacking sodium channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture. J. Neurosci. Off. J. Soc. Neurosci. 2004, 24:4030-4042.
13. Chen S., Su H., Yue C., Remy S., Royeck M., Sochivko D., et al. An increase in persistent sodium current contributes to intrinsic neuronal bursting after status epilepticus. J. Neurophysiol. 2011, 105:117-129.
14. Elger C., Bialer M., Cramer J.A., Maia J., Almeida L., Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007, 48:497-504.
15. Elger C., Halász P., Maia J., Almeida L., Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009, 50:454-463.
16. Ellerkmann R.K., Remy S., Chen J., Sochivko D., Elger C.E., Urban B.W., et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003, 119:323-333.
17. Errington A.C., Stöhr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73:157-169.
18. Gil-Nagel A., Lopes-Lima J., Almeida L., Maia J., Soares-da-Silva P. Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol. Scand. 2009, 120:281-287.
19. Gil-Nagel A., Elger C., Ben-Menachem E., Halász P., Lopes-Lima J., Gabbai A.A., et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013, 54:98-107.
20. Goldin A.L., Barchi R.L., Caldwell J.H., Hofmann F., Howe J.R., Hunter J.C., et al. Nomenclature of voltage-gated sodium channels. Neuron 2000, 28:365-368.
21. Goldin A.L. Resurgence of sodium channel research. Annu. Rev. Physiol. 2001, 63:871-894.
22. Halász P., Cramer J.A., Hodoba D., Członkowska A., Guekht A., Maia J., et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010, 51:1963-1969.
23. Hebeisen S., Brady K., Konrad D., Soares-da-Silva P. Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels. Epilepsia 2011, 52(Suppl. 6):257-258.
24. Hufnagel A., Ben-Menachem E., Gabbai A.A., Falcão A., Almeida L., Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res. 2013, 103:262-269.
25. Isom L.L., De Jongh K.S., Catterall W.A. Auxiliary subunits of voltage-gated ion channels. Neuron 1994, 12:1183-1194.
26. Lopes-Lima J., Gil-Nagel A., Maia J., Almeida L., Soares-da-Silva P. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of a one-year open-label extension of study BIA-2093-303. Epilepsia 2008, 49(Suppl. 7):441-442.
27. Lossin C. A catalog of SCN1A variants. Brain Dev. 2009, 31:114-130.
28. Lucas P.T., Meadows L.S., Nicholls J., Ragsdale D.S. An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res. 2005, 64:77-84.
29. Magistretti J., Alonso A. Biophysical properties and slow voltage-dependent inactivation of a sustained sodium current in entorhinal cortex layer-II principal neurons: a whole-cell and single-channel study. J. Gen. Physiol. 1999, 114:491-509.
30. Marini C., Scheffer I.E., Nabbout R., Suls A., De Jonghe P., Zara F., et al. The genetics of Dravet syndrome. Epilepsia 2011, 52(Suppl. 2):24-29.
31. Meadows L.S., Malhotra J., Loukas A., Thyagarajan V., Kazen-Gillespie K.A., Koopman M.C., et al. Functional and biochemical analysis of a sodium channel beta1 subunit mutation responsible for generalized epilepsy with febrile seizures plus type 1. J. Neurosci. Off. J. Soc. Neurosci. 2002, 22:10699-10709.
32. Meisler M.H., O'Brien J.E., Sharkey L.M. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J. Physiol. 2010, 588:1841-1848.
33. Oliva M., Berkovic S.F., Petrou S. Sodium channels and the neurobiology of epilepsy. Epilepsia 2012, 53:1849-1859.
34. Patino G.A., Claes L.R.F., Lopez-Santiago L.F., Slat E.A., Dondeti R.S.R., Chen C., et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29:10764-10778.
35. Patino G.A., Isom L.L. Electrophysiology and beyond multiple roles of Na+ channel β subunits in development and disease. Neurosci. Lett. 2010, 486:53-59.
36. Remy S., Urban B.W., Elger C.E., Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur. J. Neurosci. 2003, 17:2648-2658.
37. Savio-Galimberti E., Gollob M.H., Darbar D. Voltage-gated sodium channels: biophysics, pharmacology, and related channelopathies. Front. Pharmacol. 2012, 3:124.
38. Scheffer I.E., Berkovic S.F. Generalized epilepsy with febrile seizures plus: a genetic disorder with heterogeneous clinical phenotypes. Brain J. Neurol. 1997, 120(Pt 3):479-490.
39. Scheffer I.E., Harkin L.A., Grinton B.E., Dibbens L.M., Turner S.J., Zielinski M.A., et al. Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain J. Neurol. 2007, 130:100-109.
40. Sekerli M., Del Negro C.A., Lee R.H., Butera R.J. Estimating action potential thresholds from neuronal time-series: new metrics and evaluation of methodologies. IEEE Trans. Biomed. Eng. 2004, 51:1665-1672.
41. Sheets P.L., Heers C., Stoehr T., Cummins T.R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 2008, 326:89-99.
42. Soares-da-Silva P., Hebeisen S. Slow and fast inactivation of voltage-gated sodium channels by eslicarbazepine and carbamazepine. Epilepsia 2012, 53(Suppl. 5):54.
43. Stafstrom C.E. Persistent sodium current and its role in epilepsy. Epilepsy Curr. Am. Epilepsy Soc. 2007, 7:15-22.
44. Uebachs M., Opitz T., Royeck M., Dickhof G., Horstmann M.-T., Isom L.L., et al. Efficacy loss of the anticonvulsant carbamazepine in mice lacking sodium channel beta subunits via paradoxical effects on persistent sodium currents. J. Neurosci. Off. J. Soc. Neurosci. 2010, 30:8489-8501.
45. Uebachs M., Albus C., Opitz T., Isom L., Niespodziany I., Wolff C., et al. Loss of β1 accessory Na+ channel subunits causes failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na+ currents. Epilepsia 2012, 53:1959-1967.
46. Wallace R.H., Wang D.W., Singh R., Scheffer I.E., George A.L., Phillips H.A., et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat. Genet. 1998, 19:366-370.
47. Wiebe S., Jette N. Pharmacoresistance and the role of surgery in difficult to treat epilepsy. Nat. Rev. Neurol. 2012, 8:669-677.
48. Yu F.H., Catterall W.A. Overview of the voltage-gated sodium channel family. Genome Biol. 2003, 4:207.
49. Yu F.H., Westenbroek R.E., Silos-Santiago I., McCormick K.A., Lawson D., Ge P., et al. Sodium channel beta4, a new disulfide-linked auxiliary subunit with similarity to beta2. J. Neurosci. Off. J. Soc. Neurosci. 2003, 23:7577-7585.
50. Yue C., Remy S., Su H., Beck H., Yaari Y. Proximal persistent Na+ channels drive spike afterdepolarizations and associated bursting in adult CA1 pyramidal cells. J. Neurosci. Off. J. Soc. Neurosci. 2005, 25:9704-9720.